Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Pillar Of Eisai’s Growth Strategy Misses Primary Endpoint In First Phase III Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Eisai-acquired Morphotek lead candidate farletuzumab sees disappointing results in platinum-sensitive ovarian cancer.

You may also be interested in...

Deal Watch: Allergan, Regeneron Both Look To Hydrogel Tech

Most of the significant deal-making action during the past week took place in Asia as Piramal made a play to increase its injectables business, an Eisai affiliate out-licensed rights to ovarian cancer candidate farletuzumab, and EpimAb and Kymab agreed to collaborate on bispecific antibody therapeutics.

Eisai Will Try For Halaven Label Expansion, Despite Phase III Failure

Even though Eisai’s Halaven showed an unprecedented overall survival effect in a very tough-to-treat breast cancer population, the drug appears to have flopped in a head-to-head study against Xeloda in an earlier line of therapy. Nevertheless, Eisai vows to pursue a regulatory filing that would expand the drug’s label, as planned.

Merck Gains Phase III Drug/Companion Diagnostic In Deal With Endocyte

Merck will acquire rights to develop and commercialize Endocyte’s vintafolide, in Phase III development for ovarian cancer, in exchange for $120 million upfront and up to $880 million in milestones.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts